Neonatal Diabetes Mellitus Due to KCNJ11 (KIR6.2) Mutation Successfully Treated with Sulfonylurea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Neonatal diabetes mellitus (NDM) is a rare disease that occurs at less than 6 months of age and is presumably caused by a mutation in the gene that affects pancreatic beta-cell function. Approximately 80% of NDM cases reveal a known genetic mutation, and mutations in potassium inwardly rectifying channel subfamily J member 11 (KCNJ11) and ABCC8 affecting the pancreatic beta-cell adenosine triphosphate-sensitive potassium channel may be treated with oral sulfonylurea. Early recognition of mutations in KCNJ11 and ABCC8 is important because early administration of sulfonylurea can not only control blood glucose levels but also improve neurodevelopmental outcomes. In the present study, we report a case of NDM that initially presented as diabetic ketoacidosis at the age of 1 month, accompanied by seizures during hospitalization. After confirmation of the KCNJ11 gene mutation (c.989A>C), we started administering oral sulfonylurea (glimepiride) at the age of 2 months. After gradually increasing the dosage of glimepiride, insulin was discontinued at the age of 3 months. To date, the infant’s blood glucose levels have been well controlled without significant hypoglycemic events. No further episodes of seizures have occurred, and his developmental status is favorable.
Abstract
Neonatal diabetes mellitus (NDM) is a rare disease that occurs at less than 6 months of age and is presumably caused by a mutation in the gene that affects pancreatic beta-cell function. Approximately 80% of NDM cases reveal a known genetic mutation, and mutations in potassium inwardly rectifying channel subfamily J member 11 (KCNJ11) and ABCC8 affecting the pancreatic beta-cell adenosine triphosphate-sensitive potassium channel may be treated with oral sulfonylurea. Early recognition of mutations in KCNJ11 and ABCC8 is important because early administration of sulfonylurea can not only control blood glucose levels but also improve neurodevelopmental outcomes. In the present study, we report a case of NDM that initially presented as diabetic ketoacidosis at the age of 1 month, accompanied by seizures during hospitalization. After confirmation of the KCNJ11 gene mutation (c.989A>C), we started administering oral sulfonylurea (glimepiride) at the age of 2 months. After gradually increasing the dosage of glimepiride, insulin was discontinued at the age of 3 months. To date, the infant’s blood glucose levels have been well controlled without significant hypoglycemic events. No further episodes of seizures have occurred, and his developmental status is favorable.
참고문헌 (16)
- Letourneau LR, "Diabetes presentation in infancy : high risk of diabetic ketoacidosis", Diabetes Care, 40, pp.e147~e148 (2017)
- Nansseu JR, "Incidence, prevalence and genetic determinants of neonatal diabetes mellitus: a systematic review and meta-analysis protocol", Syst Rev, 5, pp.188~ (2016)
- De Franco E, "The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study", Lancet, 386, pp.957~963 (2015)
- Shah RP, "Visuomotor performance in KCNJ11-related neonatal diabetes is impaired in children with DEND-associated mutations and may be improved by early treatment with sulfonylureas", Diabetes Care, 35, pp.2086~2088 (2012)
- Bowman P, "Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11mutations : an international cohort study", Lancet Diabetes Endocrinol, 6, pp.637~646 (2018)
- Brereton MF, "Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic β-cells", Nat Commun, 7, pp.13496~ (2016)
- Ashcroft FM, "Neonatal diabetes and the KATP channel : from mutation to therapy", Trends Endocrinol Metab, 28, pp.377~387 (2017)
- Garcin L, "Neonatal diabetes due to potassium channel mutation : response to sulfonylurea according to the genotype", Pediatr Diabetes, 21, pp.932~941 (2020)
- Lanning MS, "Hypoglycemia in sulfonylurea-treated KCNJ11-neonatal diabetes : mild-moderate symptomatic episodes occur infrequently but none involving unconsciousness or seizures", Pediatr Diabetes, 19, pp.393~397 (2018)
- 김민선, "Sulfonylurea Therapy in Two Korean Patients with Insulin-treatedNeonatal Diabetes due to Heterozygous Mutations of the KCNJ11Gene Encoding Kir6.2", Journal of Korean Medical Science, 22(4), pp.616~620 (2007), 대한의학회
- Heo JW, "Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene : a case report", Diabetes Res Clin Pract, 100, pp.e1~e2 (2013)
- 안성연, "Successful sulfonylurea treatment in a patient with permanent neonatal diabetes mellitus with a novel KCNJ11 mutation", Clinical and Experimental Pediatrics, 58(8), pp.309~312 (2015), 대한소아청소년과학회
- 조자향, "DEND Syndrome with Heterozygous KCNJ11 Mutation Successfully Treated with Sulfonylurea", Journal of Korean Medical Science, 32(6), pp.1042~1045 (2017), 대한의학회
- 윤종서, "Successful switching from insulin to sulfonylurea in a 3-month-old infant with diabetes due to p.G53D mutation in KCNJ11", Annals of Pediatric Endocrinology & Metabolism, 23(3), pp.154~157 (2018), 대한소아내분비학회
- Carmody D, "Sulfonylurea treatment before genetic testing in neonatal diabetes : pros and cons", J Clin Endocrinol Metab, 99, pp.E2709~E2714 (2014)
- Yildiz M, "Emergence of insulin resistance following empirical glibenclamide therapy : a case report of neonatal diabetes with a recessive INS gene mutation", J Pediatr Endocrinol Metab, 31, pp.345~348 (2018)